Chemed Reports Third-Quarter 2014 Results
Consolidated operating results:
-
Revenue increased 5.1% to
$358 million -
GAAP Diluted EPS increased 47.9% to
$1.39 -
Adjusted Diluted EPS increased 8.8% to
$1.48
VITAS segment operating results:
-
Net Patient Revenue of
$265 million , an increase of 4.5% - Average Daily Census (ADC) of 14,639, an increase of 2.8%
- Admissions of 15,653, an increase of 7.5%
-
Net Income, including litigation costs, of
$21.6 million , an increase of 47.8% -
Adjusted EBITDA of
$38.3 million , an increase of 2.7% - Adjusted EBITDA margin of 14.4%, a decrease of 24 basis points
Roto-Rooter segment operating results:
-
Revenue of
$93.0 million , an increase of 7.0% -
Net Income of
$9.8 million , an increase of 20.4% -
Adjusted EBITDA of
$17.3 million , an increase of 6.8% - Adjusted EBITDA margin of 18.6%, a decrease of 4 basis points
VITAS
Net revenue for VITAS was
In the third quarter of 2014, VITAS recorded
Of the 36 remaining
Average revenue per patient per day in the quarter, excluding the impact
of Medicare Cap, was
The third quarter of 2014 gross margin, excluding the impact of
Selling, general and administrative expense was
Roto-Rooter
Roto-Rooter’s plumbing and drain cleaning business generated sales of
Roto-Rooter’s gross margin in the quarter was 46.9%, a 34 basis point
decline when compared to the third quarter of 2013. Adjusted EBITDA in
the third quarter of 2014 totaled
Chemed Consolidated
As of
In
Capital expenditures through
The Company repurchased
Guidance for 2014
VITAS revenue growth was constrained in the first half of 2014. This was
primarily the result of the 2.0%
Full-year 2014 revenue growth for VITAS, prior to Medicare Cap, is
estimated to be in the range of 1% to 2%. Admissions in 2014 are
estimated to increase 2% and full-year Adjusted EBITDA margin, prior to
Medicare Cap, is estimated to be 14.5% to 15.0%. Medicare Cap is
estimated to be
Roto-Rooter is forecasted to achieve full-year 2014 revenue growth of 4% to 5%. This revenue estimate is based upon increased job pricing of approximately 2.0%. Adjusted EBITDA margin for 2014 is estimated in the range of 19.0% to 19.5%.
Management estimates that full-year 2014 earnings per diluted share,
excluding non-cash expense for stock options, the non-cash interest
expense related to the accounting for convertible debt, litigation and
other discrete items, will be in the range of
Conference Call
A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (888) 286-8010 for U.S. and Canadian callers and (617) 801-6888 for international callers and will be available for one week following the live call. The replay passcode is 99376839. An archived webcast will also be available at www.chemed.com.
This press release contains information about Chemed’s EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS, which are not measures derived in
accordance with GAAP and which exclude components that are important to
understanding Chemed’s financial performance. In reporting its operating
results,
Forward-Looking Statements
Certain statements contained in this press release and the accompanying
tables are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "hope," "anticipate," "plan" and similar expressions identify
forward-looking statements, which speak only as of the date the
statement was made.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES |
||||||||||||||||||||||||||
CONSOLIDATED STATEMENT OF INCOME | ||||||||||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
September 30, | September 30, | |||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||||||||||
Service revenues and sales | $ | 358,389 | $ | 340,886 | $ | 1,076,871 | $ | 1,064,725 | ||||||||||||||||||
Cost of services provided and goods sold | 256,445 | 243,184 | 771,271 | 762,850 | ||||||||||||||||||||||
Selling, general and administrative expenses (aa) | 53,566 | 48,870 | 162,886 | 157,537 | ||||||||||||||||||||||
Depreciation | 7,450 | 6,971 | 21,871 | 20,665 | ||||||||||||||||||||||
Amortization | 717 | 1,190 | 2,461 | 3,498 | ||||||||||||||||||||||
Other operating expenses (bb) | - | 11,461 | - | 26,221 | ||||||||||||||||||||||
Total costs and expenses | 318,178 | 311,676 | 958,489 | 970,771 | ||||||||||||||||||||||
Income from operations | 40,211 | 29,210 | 118,382 | 93,954 | ||||||||||||||||||||||
Interest expense | (980 | ) | (3,500 | ) | (7,224 | ) | (11,291 | ) | ||||||||||||||||||
Other income/(expense)--net (cc) | 705 | (90 | ) | 2,277 | 3,312 | |||||||||||||||||||||
Income before income taxes | 39,936 | 25,620 | 113,435 | 85,975 | ||||||||||||||||||||||
Income taxes | (15,351 | ) | (8,188 | ) | (43,913 | ) | (31,657 | ) | ||||||||||||||||||
Net income | $ | 24,585 | $ | 17,432 | $ | 69,522 | $ | 54,318 | ||||||||||||||||||
Earnings Per Share |
||||||||||||||||||||||||||
Net income | $ | 1.44 | $ | 0.96 | $ | 4.03 | $ | 2.95 | ||||||||||||||||||
Average number of shares outstanding | 17,039 | 18,184 | 17,263 | 18,436 | ||||||||||||||||||||||
Diluted Earnings Per Share | ||||||||||||||||||||||||||
Net income | $ | 1.39 | $ | 0.94 | $ | 3.87 | $ | 2.89 | ||||||||||||||||||
Average number of shares outstanding | 17,627 | 18,522 | 17,968 | 18,824 | ||||||||||||||||||||||
(aa) | Selling, general and administrative ("SG&A") expenses comprise (in thousands): | |||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||||||||||
SG&A expenses before long-term incentive compensation and the impact of market gains and losses of deferred compensation plans |
$ | 51,668 | $ | 49,004 | $ | 158,190 | $ | 154,030 | ||||||||||||||||||
Market value gains/(losses) related to assets held in deferred compensation trusts |
896 | (189 | ) | 2,708 | 2,346 | |||||||||||||||||||||
Long-term incentive compensation | 1,002 | 55 | 1,988 | 1,161 | ||||||||||||||||||||||
Total SG&A expenses | $ | 53,566 | $ | 48,870 | $ | 162,886 | $ | 157,537 | ||||||||||||||||||
(bb) | Other operating expenses comprise (in thousands): | |||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||||||||||
Litigation settlement of VITAS segment | $ | - | $ | 10,500 | $ | - | $ | 10,500 | ||||||||||||||||||
Litigation settlements of Roto-Rooter segment | - | 961 | - | 15,721 | ||||||||||||||||||||||
Total other operating expenses | $ | - | $ | 11,461 | $ | - | $ | 26,221 | ||||||||||||||||||
(cc) | Other income/(expense)--net comprises (in thousands): | |||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||||||||||
|
||||||||||||||||||||||||||
Market value gains/(losses) related to assets held in deferred compensation trusts |
$ | 896 |
$ |
(189 |
) |
$ | 2,708 |
$ |
2,346 |
|||||||||||||||||
Loss on disposal of property and equipment | (167 | ) |
(101 |
) |
(493 | ) |
(180 |
) |
||||||||||||||||||
Interest income | (13 | ) |
192 |
(5 | ) |
1,165 |
||||||||||||||||||||
Other | (11 | ) |
8 |
67 |
(19 |
) |
||||||||||||||||||||
Total other income--net | $ | 705 | $ |
(90 |
) |
$ | 2,277 | $ |
3,312 |
|||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||
CONSOLIDATED BALANCE SHEET | ||||||||||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||||||||||
September 30, | ||||||||||||||||||||
2014 |
2013 |
|||||||||||||||||||
Assets |
||||||||||||||||||||
Current assets | ||||||||||||||||||||
Cash and cash equivalents | $ | 18,562 | $ | 83,204 | ||||||||||||||||
Accounts receivable less allowances | 132,340 | 80,117 | ||||||||||||||||||
Inventories | 6,385 | 6,729 | ||||||||||||||||||
Current deferred income taxes | 14,543 | 25,101 | ||||||||||||||||||
Prepaid income taxes | 3,488 | 3,538 | ||||||||||||||||||
Prepaid expenses | 13,420 | 17,684 | ||||||||||||||||||
Total current assets | 188,738 | 216,373 | ||||||||||||||||||
Investments of deferred compensation plans held in trust | 47,780 | 40,683 | ||||||||||||||||||
Properties and equipment, at cost less accumulated depreciation | 101,845 | 89,800 | ||||||||||||||||||
Identifiable intangible assets less accumulated amortization | 56,158 | 56,979 | ||||||||||||||||||
Goodwill | 466,844 | 466,940 | ||||||||||||||||||
Other assets | 8,143 | 10,765 | ||||||||||||||||||
Total Assets | $ | 869,508 | $ | 881,540 | ||||||||||||||||
Liabilities | ||||||||||||||||||||
Current liabilities | ||||||||||||||||||||
Accounts payable | $ | 57,067 | $ | 44,523 | ||||||||||||||||
Current portion of long-term debt | 20,425 | 181,340 | ||||||||||||||||||
Income taxes | 4,608 | 5,529 | ||||||||||||||||||
Accrued insurance | 39,927 | 41,737 | ||||||||||||||||||
Accrued compensation | 50,412 | 46,689 | ||||||||||||||||||
Accrued legal | 685 | 33,304 | ||||||||||||||||||
Other current liabilities | 24,131 | 23,232 | ||||||||||||||||||
Total current liabilities | 197,255 | 376,354 | ||||||||||||||||||
Deferred income taxes | 27,853 | 27,454 | ||||||||||||||||||
Long-term debt | 153,125 | - | ||||||||||||||||||
Deferred compensation liabilities | 47,736 | 39,406 | ||||||||||||||||||
Other liabilities | 11,108 | 11,499 | ||||||||||||||||||
Total Liabilities | 437,077 | 454,713 | ||||||||||||||||||
Stockholders' Equity | ||||||||||||||||||||
Capital stock | 33,199 | 32,086 | ||||||||||||||||||
Paid-in capital | 528,973 | 469,934 | ||||||||||||||||||
Retained earnings | 745,077 | 666,894 | ||||||||||||||||||
Treasury stock, at cost | (877,067 | ) | (744,210 | ) | ||||||||||||||||
Deferred compensation payable in Company stock | 2,249 | 2,123 | ||||||||||||||||||
Total Stockholders' Equity | 432,431 | 426,827 | ||||||||||||||||||
Total Liabilities and Stockholders' Equity | $ | 869,508 | $ | 881,540 | ||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||
CONSOLIDATED STATEMENT OF CASH FLOWS |
||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||
Nine Months Ended September 30, | ||||||||||||||||||||
2014 |
2013 | |||||||||||||||||||
Cash Flows from Operating Activities | ||||||||||||||||||||
Net income | $ | 69,522 | $ | 54,318 | ||||||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||||||||||||||
Depreciation and amortization | 24,332 | 24,163 | ||||||||||||||||||
Provision for deferred income taxes | 5,630 | (11,681 | ) | |||||||||||||||||
Provision for uncollectible accounts receivable | 9,573 | 8,211 | ||||||||||||||||||
Amortization of discount on convertible notes | 3,392 | 6,450 | ||||||||||||||||||
Stock option expense | 3,430 | 4,732 | ||||||||||||||||||
Amortization of debt issuance costs | 697 | 1,421 | ||||||||||||||||||
Noncash long-term incentive compensation | 1,988 | 1,161 | ||||||||||||||||||
Changes in operating assets and liabilities, excluding amounts acquired in business combinations: |
||||||||||||||||||||
Decrease/(increase) in accounts receivable | (50,027 | ) | 5,293 | |||||||||||||||||
Decrease in inventories | 318 | 329 | ||||||||||||||||||
Decrease/(increase) in prepaid expenses | 4,398 | (6,183 | ) | |||||||||||||||||
Increase/(decrease) in accounts payable and other current liabilities |
(29,680 | ) | 48,967 | |||||||||||||||||
Increase in income taxes | 8,186 | 1,923 | ||||||||||||||||||
Increase in other assets | (3,138 | ) | (5,002 | ) | ||||||||||||||||
Increase in other liabilities | 5,370 | 3,978 | ||||||||||||||||||
Excess tax benefit on share-based compensation | (3,737 | ) | (2,507 | ) | ||||||||||||||||
Other sources | 755 | 285 | ||||||||||||||||||
Net cash provided by operating activities | 51,009 | 135,858 | ||||||||||||||||||
Cash Flows from Investing Activities | ||||||||||||||||||||
Capital expenditures | (31,745 | ) | (18,887 | ) | ||||||||||||||||
Business combinations, net of cash acquired | (250 | ) | (2,210 | ) | ||||||||||||||||
Other sources | 189 | 139 | ||||||||||||||||||
Net cash used by investing activities | (31,806 | ) | (20,958 | ) | ||||||||||||||||
Cash Flows from Financing Activities | ||||||||||||||||||||
Proceeds from revolving line of credit | 308,600 | - | ||||||||||||||||||
Payments on revolving line of credit | (233,800 | ) | - | |||||||||||||||||
Payments on other long-term debt | (188,206 | ) | - | |||||||||||||||||
Proceeds from other long-term debt | 100,000 | - | ||||||||||||||||||
Purchases of treasury stock | (99,103 | ) | (89,611 | ) | ||||||||||||||||
Increase/(decrease) in cash overdrafts payable | 22,233 | (10,928 | ) | |||||||||||||||||
Proceeds from exercise of stock options | 22,123 | 13,125 | ||||||||||||||||||
Dividends paid | (10,558 | ) | (10,459 | ) | ||||||||||||||||
Capital stock surrendered to pay taxes on stock-based compensation | (6,121 | ) | (4,280 | ) | ||||||||||||||||
Excess tax benefit on share-based compensation | 3,737 | 2,507 | ||||||||||||||||||
Retirement of warrants | (2,645 | ) |
- |
|||||||||||||||||
Debt issuances costs | (939 | ) | (1,108 | ) | ||||||||||||||||
Other sources/(uses) | (380 | ) | (473 | ) | ||||||||||||||||
Net cash used by financing activities | (85,059 | ) | (101,227 | ) | ||||||||||||||||
Increase/(Decrease) in Cash and Cash Equivalents | (65,856 | ) | 13,673 | |||||||||||||||||
Cash and cash equivalents at beginning of year |
84,418 |
69,531 |
||||||||||||||||||
Cash and cash equivalents at end of period | $ | 18,562 | $ | 83,204 | ||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | ||||||||||||||||||||||
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013 | ||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||
Chemed | ||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate |
Consolidated |
|||||||||||||||||||
2014 | ||||||||||||||||||||||
Service revenues and sales | $ | 265,384 | $ | 93,005 | $ | - | $ | 358,389 | ||||||||||||||
Cost of services provided and goods sold | 207,105 | 49,340 | - | 256,445 | ||||||||||||||||||
Selling, general and administrative expenses (a) | 20,224 | 25,682 | 7,660 | 53,566 | ||||||||||||||||||
Depreciation | 4,530 | 2,772 | 148 | 7,450 | ||||||||||||||||||
Amortization | 205 | 114 | 398 | 717 | ||||||||||||||||||
Total costs and expenses | 232,064 | 77,908 | 8,206 | 318,178 | ||||||||||||||||||
Income/(loss) from operations | 33,320 | 15,097 | (8,206 | ) | 40,211 | |||||||||||||||||
Interest expense (a) | (55 | ) | (87 | ) | (838 | ) | (980 | ) | ||||||||||||||
Intercompany interest income/(expense) | 1,660 | 760 | (2,420 | ) | - | |||||||||||||||||
Other income/(expense)—net | (189 | ) | (2 | ) | 896 | 705 | ||||||||||||||||
Income/(loss) before income taxes | 34,736 | 15,768 | (10,568 | ) | 39,936 | |||||||||||||||||
Income taxes (a) | (13,143 | ) | (5,920 | ) | 3,712 | (15,351 | ) | |||||||||||||||
Net income/(loss) | $ | 21,593 | $ | 9,848 | $ | (6,856 | ) | $ | 24,585 | |||||||||||||
2013 | ||||||||||||||||||||||
Service revenues and sales | $ | 254,001 | $ | 86,885 | $ | - | $ | 340,886 | ||||||||||||||
Cost of services provided and goods sold | 197,387 | 45,797 | - | 243,184 | ||||||||||||||||||
Selling, general and administrative expenses (b) | 18,637 | 25,009 | 5,224 | 48,870 | ||||||||||||||||||
Depreciation | 4,545 | 2,292 | 134 | 6,971 | ||||||||||||||||||
Amortization | 538 | 151 | 501 | 1,190 | ||||||||||||||||||
Other operating expenses (a) | 10,500 | 961 | - | 11,461 | ||||||||||||||||||
Total costs and expenses | 231,607 | 74,210 | 5,859 | 311,676 | ||||||||||||||||||
Income/(loss) from operations | 22,394 | 12,675 | (5,859 | ) | 29,210 | |||||||||||||||||
Interest expense (b) | (48 | ) | (82 | ) | (3,370 | ) | (3,500 | ) | ||||||||||||||
Intercompany interest income/(expense) | 1,231 | 579 | (1,810 | ) | - | |||||||||||||||||
Other income/(expense)—net | 73 | 8 | (171 | ) | (90 | ) | ||||||||||||||||
Income/(loss) before income taxes | 23,650 | 13,180 | (11,210 | ) | 25,620 | |||||||||||||||||
Income taxes (b) | (9,042 | ) | (4,999 | ) | 5,853 | (8,188 | ) | |||||||||||||||
Net income/(loss) | $ | 14,608 | $ | 8,181 | $ | (5,357 | ) | $ | 17,432 | |||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | ||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | ||||||||||||||||||||||
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013 | ||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||
Chemed | ||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||||
2014 | ||||||||||||||||||||||
Service revenues and sales | $ | 789,822 | $ | 287,049 | $ | - | $ | 1,076,871 | ||||||||||||||
Cost of services provided and goods sold | 618,315 | 152,956 | - | 771,271 | ||||||||||||||||||
Selling, general and administrative expenses (a) | 62,939 | 78,569 | 21,378 | 162,886 | ||||||||||||||||||
Depreciation | 13,709 | 7,732 | 430 | 21,871 | ||||||||||||||||||
Amortization | 829 | 397 | 1,235 | 2,461 | ||||||||||||||||||
Total costs and expenses | 695,792 | 239,654 | 23,043 | 958,489 | ||||||||||||||||||
Income/(loss) from operations | 94,030 | 47,395 | (23,043 | ) | 118,382 | |||||||||||||||||
Interest expense (a) | (167 | ) | (295 | ) | (6,762 | ) | (7,224 | ) | ||||||||||||||
Intercompany interest income/(expense) | 4,520 | 2,090 | (6,610 | ) | - | |||||||||||||||||
Other income/(expense)—net | (577 | ) | 137 | 2,717 | 2,277 | |||||||||||||||||
Income/(loss) before income taxes | 97,806 | 49,327 | (33,698 | ) | 113,435 | |||||||||||||||||
Income taxes (a) | (37,161 | ) | (18,728 | ) | 11,976 | (43,913 | ) | |||||||||||||||
Net income/(loss) | $ | 60,645 | $ | 30,599 | $ | (21,722 | ) | $ | 69,522 | |||||||||||||
2013 | ||||||||||||||||||||||
Service revenues and sales | $ | 788,896 | $ | 275,829 | $ | - | $ | 1,064,725 | ||||||||||||||
Cost of services provided and goods sold | 616,334 | 146,516 | - | 762,850 | ||||||||||||||||||
Selling, general and administrative expenses (b) | 61,304 | 76,901 | 19,332 | 157,537 | ||||||||||||||||||
Depreciation | 13,579 | 6,685 | 401 | 20,665 | ||||||||||||||||||
Amortization | 1,564 | 454 | 1,480 | 3,498 | ||||||||||||||||||
Other operating expenses (a) | 10,500 | 15,721 | - | 26,221 | ||||||||||||||||||
Total costs and expenses | 703,281 | 246,277 | 21,213 | 970,771 | ||||||||||||||||||
Income/(loss) from operations | 85,615 | 29,552 | (21,213 | ) | 93,954 | |||||||||||||||||
Interest expense (b) | (145 | ) | (239 | ) | (10,907 | ) | (11,291 | ) | ||||||||||||||
Intercompany interest income/(expense) | 2,940 | 1,443 | (4,383 | ) | - | |||||||||||||||||
Other income/(expense)—net | 878 | 42 | 2,392 | 3,312 | ||||||||||||||||||
Income/(loss) before income taxes | 89,288 | 30,798 | (34,111 | ) | 85,975 | |||||||||||||||||
Income taxes (b) | (34,051 | ) | (11,580 | ) | 13,974 | (31,657 | ) | |||||||||||||||
Net income/(loss) | $ | 55,237 | $ | 19,218 | $ | (20,137 | ) | $ | 54,318 | |||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | ||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | ||||||||||||||||||||||||
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013 | ||||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||||
Chemed | ||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||||||
2014 | ||||||||||||||||||||||||
Net income/(loss) | $ | 21,593 | $ | 9,848 | $ | (6,856 | ) | $ | 24,585 | |||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Interest expense | 55 | 87 | 838 | 980 | ||||||||||||||||||||
Income taxes | 13,143 | 5,920 | (3,712 | ) | 15,351 | |||||||||||||||||||
Depreciation | 4,530 | 2,772 | 148 | 7,450 | ||||||||||||||||||||
Amortization | 205 | 114 | 398 | 717 | ||||||||||||||||||||
EBITDA | 39,526 | 18,741 | (9,184 | ) | 49,083 | |||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Intercompany interest expense/(income) | (1,660 | ) | (760 | ) | 2,420 | - | ||||||||||||||||||
Interest income | 23 | (9 | ) | (1 | ) | 13 | ||||||||||||||||||
Expenses related to OIG investigation | 450 | - | - | 450 | ||||||||||||||||||||
Net recoveries related to litigation settlements |
- | (234 | ) | - | (234 | ) | ||||||||||||||||||
Advertising cost adjustment (c) | - | (483 | ) | - | (483 | ) | ||||||||||||||||||
Long-term incentive compensation | - | - | 1,002 | 1,002 | ||||||||||||||||||||
Stock option expense | - | - | 977 | 977 | ||||||||||||||||||||
Expenses of securities litigation | - | - | 138 | 138 | ||||||||||||||||||||
Adjusted EBITDA | $ | 38,339 | $ | 17,255 | $ | (4,648 | ) | $ | 50,946 | |||||||||||||||
2013 | ||||||||||||||||||||||||
Net income/(loss) | $ | 14,608 | $ | 8,181 | $ | (5,357 | ) | $ | 17,432 | |||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Interest expense | 48 | 82 | 3,370 | 3,500 | ||||||||||||||||||||
Income taxes | 9,042 | 4,999 | (5,853 | ) | 8,188 | |||||||||||||||||||
Depreciation | 4,545 | 2,292 | 134 | 6,971 | ||||||||||||||||||||
Amortization | 538 | 151 | 501 | 1,190 | ||||||||||||||||||||
EBITDA | 28,781 | 15,705 | (7,205 | ) | 37,281 | |||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Intercompany interest expense/(income) | (1,231 | ) | (579 | ) | 1,810 | - | ||||||||||||||||||
Interest income | (163 | ) | (10 | ) | (19 | ) | (192 | ) | ||||||||||||||||
Litigation settlements | 10,500 | 961 | - | 11,461 | ||||||||||||||||||||
Net expenses/(cost recovery) related to OIG investigation | (591 | ) | - | - | (591 | ) | ||||||||||||||||||
Acquisition expenses | 18 | 3 | - | 21 | ||||||||||||||||||||
Expenses related to litigation settlements | - | 443 | - | 443 | ||||||||||||||||||||
Advertising cost adjustment (c) | - | (369 | ) | - | (369 | ) | ||||||||||||||||||
Stock option expense | - | - | 1,629 | 1,629 | ||||||||||||||||||||
Long-term incentive compensation | - | - | 55 | 55 | ||||||||||||||||||||
Expenses of securities litigation | - | - | 1 | 1 | ||||||||||||||||||||
Adjusted EBITDA | $ | 37,314 | $ | 16,154 | $ | (3,729 | ) | $ | 49,739 | |||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | ||||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | ||||||||||||||||||||||||
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013 | ||||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||||
Chemed | ||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||||||
2014 | ||||||||||||||||||||||||
Net income/(loss) | $ | 60,645 | $ | 30,599 | $ | (21,722 | ) | $ | 69,522 | |||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Interest expense | 167 | 295 | 6,762 | 7,224 | ||||||||||||||||||||
Income taxes | 37,161 | 18,728 | (11,976 | ) | 43,913 | |||||||||||||||||||
Depreciation | 13,709 | 7,732 | 430 | 21,871 | ||||||||||||||||||||
Amortization | 829 | 397 | 1,235 | 2,461 | ||||||||||||||||||||
EBITDA | 112,511 | 57,751 | (25,271 | ) | 144,991 | |||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Intercompany interest expense/(income) | (4,520 | ) | (2,090 | ) | 6,610 | - | ||||||||||||||||||
Interest income | 43 | (28 | ) | (10 | ) | 5 | ||||||||||||||||||
Net expense/(recoveries) related to litigation settlements |
113 | (9 | ) | - | 104 | |||||||||||||||||||
Expenses related to OIG investigation | 1,608 | - | - | 1,608 | ||||||||||||||||||||
Acquisition expenses | 1 | - | - | 1 | ||||||||||||||||||||
Advertising cost adjustment (c) | - | (1,623 | ) | - | (1,623 | ) | ||||||||||||||||||
Stock option expense | - | - | 3,430 | 3,430 | ||||||||||||||||||||
Long-term incentive compensation | - | - | 1,988 | 1,988 | ||||||||||||||||||||
Expenses of securities litigation | - | - | 327 | 327 | ||||||||||||||||||||
Adjusted EBITDA | $ | 109,756 | $ | 54,001 | $ | (12,926 | ) | $ | 150,831 | |||||||||||||||
2013 | ||||||||||||||||||||||||
Net income/(loss) | $ | 55,237 | $ | 19,218 | $ | (20,137 | ) | $ | 54,318 | |||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Interest expense | 145 | 239 | 10,907 | 11,291 | ||||||||||||||||||||
Income taxes | 34,051 | 11,580 | (13,974 | ) | 31,657 | |||||||||||||||||||
Depreciation | 13,579 | 6,685 | 401 | 20,665 | ||||||||||||||||||||
Amortization | 1,564 | 454 | 1,480 | 3,498 | ||||||||||||||||||||
EBITDA | 104,576 | 38,176 | (21,323 | ) | 121,429 | |||||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||||
Intercompany interest expense/(income) | (2,940 | ) | (1,443 | ) | 4,383 | - | ||||||||||||||||||
Interest income | (1,051 | ) | (66 | ) | (48 | ) | (1,165 | ) | ||||||||||||||||
Litigation settlements | 10,500 | 15,721 | - | 26,221 | ||||||||||||||||||||
Net expenses related to OIG investigation | 1,444 | - | - | 1,444 | ||||||||||||||||||||
Acquisition expenses | 38 | 4 | - | 42 | ||||||||||||||||||||
Expenses related to litigation settlements | - | 1,151 | - | 1,151 | ||||||||||||||||||||
Advertising cost adjustment (c) | - | (1,343 | ) | - | (1,343 | ) | ||||||||||||||||||
Cost of severance arrangements | - | 302 | - | 302 | ||||||||||||||||||||
Stock option expense | - | - | 4,732 | 4,732 | ||||||||||||||||||||
Long-term incentive compensation | - | - | 1,161 | 1,161 | ||||||||||||||||||||
Expenses of securities litigation | - | - | 4 | 4 | ||||||||||||||||||||
Adjusted EBITDA | $ | 112,567 | $ | 52,502 | $ | (11,091 | ) | $ | 153,978 | |||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | ||||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||
RECONCILIATION OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE | |||||||||||||||||||||||
(in thousands, except per share data)(unaudited) | |||||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
September 30, | September 30, | ||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||
Net income as reported | $ | 24,585 | $ | 17,432 | $ | 69,522 | $ | 54,318 | |||||||||||||||
Add/(deduct) after-tax costs of: | |||||||||||||||||||||||
Long-term incentive compensation | 634 | 34 | 1,258 | 734 | |||||||||||||||||||
Stock option expense | 615 | 1,030 | 2,159 | 2,993 | |||||||||||||||||||
Net expenses/(cost recovery) related to OIG investigation | 279 | (367 | ) | 997 | 895 | ||||||||||||||||||
Net expenses/(recoveries) related to litigation settlements |
(143 | ) |
269 |
64 |
699 |
||||||||||||||||||
Securities litigation | 88 | 1 | 207 | 3 | |||||||||||||||||||
Uncertain tax position adjustments | - | (1,782 | ) | - | (1,782 | ) | |||||||||||||||||
Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes |
- | 1,375 | 2,143 | 4,046 | |||||||||||||||||||
Litigation settlements |
|
- |
|
7,094 |
|
- |
16,061 |
||||||||||||||||
Acquisition expenses | - | 12 |
1 |
25 | |||||||||||||||||||
Loss on extinguishment of debt | - | - | - | 294 | |||||||||||||||||||
Severance arrangements | - | - | - | 184 | |||||||||||||||||||
Adjusted net income | $ | 26,058 | $ | 25,098 | $ | 76,351 | $ | 78,470 | |||||||||||||||
Diluted Earnings Per Share As Reported | |||||||||||||||||||||||
Net income | $ | 1.39 | $ | 0.94 | $ | 3.87 | $ | 2.89 | |||||||||||||||
Average number of shares outstanding | 17,627 | 18,522 | 17,968 | 18,824 | |||||||||||||||||||
Adjusted Diluted Earnings Per Share | |||||||||||||||||||||||
Net income | $ | 1.48 | $ | 1.36 | $ | 4.28 | $ | 4.17 | |||||||||||||||
Adjusted average number of shares outstanding (e) | 17,627 | 18,522 | 17,833 | 18,824 | |||||||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | |||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||||||||
OPERATING STATISTICS FOR VITAS SEGMENT | ||||||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||
September 30, | September 30, | |||||||||||||||||||||||||||
OPERATING STATISTICS | 2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||||||
Net revenue ($000) (d) | ||||||||||||||||||||||||||||
Homecare | $ | 204,965 | $ | 196,476 | $ | 600,780 | $ | 593,410 | ||||||||||||||||||||
Inpatient | 25,012 | 24,824 | 77,037 | 79,181 | ||||||||||||||||||||||||
Continuous care | 37,907 | 35,880 | 113,801 | 119,466 | ||||||||||||||||||||||||
Total before Medicare cap allowance | 267,884 | 257,180 | 791,618 | 792,057 | ||||||||||||||||||||||||
Medicare cap allowance | (2,500 | ) | (3,179 | ) | (1,796 | ) | (3,161 | ) | ||||||||||||||||||||
Total | $ | 265,384 | $ | 254,001 | $ | 789,822 | $ | 788,896 | ||||||||||||||||||||
Net revenue as a percent of total before Medicare cap allowance | ||||||||||||||||||||||||||||
Homecare | 76.5 | % | 76.4 | % | 75.9 | % | 74.9 | % | ||||||||||||||||||||
Inpatient | 9.3 | 9.7 | 9.7 | 10.0 | ||||||||||||||||||||||||
Continuous care | 14.2 | 14.0 | 14.5 | 15.2 | ||||||||||||||||||||||||
Total before Medicare cap allowance | 100.0 | 100.1 | 100.1 | 100.1 | ||||||||||||||||||||||||
Medicare cap allowance | (0.9 | ) | (1.3 | ) | (0.2 | ) | (0.4 | ) | ||||||||||||||||||||
Total | 99.1 | % | 98.8 | % | 99.9 | % | 99.7 | % | ||||||||||||||||||||
Average daily census ("ADC") (days) | ||||||||||||||||||||||||||||
Homecare | 10,662 | 10,373 | 10,562 | 10,482 | ||||||||||||||||||||||||
Nursing home | 2,999 | 2,911 | 2,940 | 2,928 | ||||||||||||||||||||||||
Routine homecare | 13,661 | 13,284 | 13,502 | 13,410 | ||||||||||||||||||||||||
Inpatient | 417 | 417 | 429 | 440 | ||||||||||||||||||||||||
Continuous care | 561 | 540 | 568 | 600 | ||||||||||||||||||||||||
Total | 14,639 | 14,241 | 14,499 | 14,450 | ||||||||||||||||||||||||
Total Admissions | 15,653 | 14,555 | 47,777 | 47,413 | ||||||||||||||||||||||||
Total Discharges | 15,460 | 14,971 | 47,139 | 47,603 | ||||||||||||||||||||||||
Average length of stay (days) | 83.7 | 82.2 | 82.4 | 81.3 | ||||||||||||||||||||||||
Median length of stay (days) | 15.0 | 16.0 | 15.0 | 15.0 | ||||||||||||||||||||||||
ADC by major diagnosis | ||||||||||||||||||||||||||||
Neurological | 32.7 | % | 37.8 | % | 35.0 | % | 36.8 | % | ||||||||||||||||||||
Cancer | 17.3 | 17.1 | 17.4 | 17.0 | ||||||||||||||||||||||||
Cardio | 17.6 | 13.9 | 16.6 | 12.8 | ||||||||||||||||||||||||
Respiratory | 8.0 | 7.8 | 7.9 | 7.5 | ||||||||||||||||||||||||
Other | 24.4 | 23.4 | 23.1 | 25.9 | ||||||||||||||||||||||||
Total | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||||||||||||||
Admissions by major diagnosis | ||||||||||||||||||||||||||||
Neurological | 18.2 | % | 21.0 | % | 20.6 | % | 20.3 | % | ||||||||||||||||||||
Cancer | 34.0 | 34.4 | 33.3 | 33.0 | ||||||||||||||||||||||||
Cardio | 15.2 | 13.8 | 14.8 | 13.0 | ||||||||||||||||||||||||
Respiratory | 9.1 | 9.0 | 9.5 | 9.3 | ||||||||||||||||||||||||
Other | 23.5 | 21.8 | 21.8 | 24.4 | ||||||||||||||||||||||||
Total | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||||||||||||||
Direct patient care margins (f) | ||||||||||||||||||||||||||||
Routine homecare | 53.8 | % | 52.5 | % | 53.4 | % | 52.2 | % | ||||||||||||||||||||
Inpatient | 4.9 | 1.7 | 5.4 | 5.6 | ||||||||||||||||||||||||
Continuous care | 17.4 | 14.8 | 17.2 | 15.8 | ||||||||||||||||||||||||
Homecare margin drivers (dollars per patient day) | ||||||||||||||||||||||||||||
Labor costs | $ | 53.65 | $ | 54.64 | $ | 54.31 | $ | 55.61 | ||||||||||||||||||||
Drug costs | 6.64 | 7.52 | 7.04 | 7.55 | ||||||||||||||||||||||||
Home medical equipment |
6.68 |
6.67 |
6.69 |
6.69 | ||||||||||||||||||||||||
Medical supplies | 3.22 | 2.83 | 3.20 | 2.96 | ||||||||||||||||||||||||
Inpatient margin drivers (dollars per patient day) | ||||||||||||||||||||||||||||
Labor costs | $ | 345.18 | $ | 354.09 | $ | 344.05 | $ | 339.84 | ||||||||||||||||||||
Continuous care margin drivers (dollars per patient day) | ||||||||||||||||||||||||||||
Labor costs | $ | 584.99 | $ | 594.25 | $ | 586.60 | $ | 592.15 | ||||||||||||||||||||
Bad debt expense as a percent of revenues | 1.0 | % | 0.9 | % | 1.0 | % | 0.9 | % | ||||||||||||||||||||
Accounts receivable -- | ||||||||||||||||||||||||||||
Days of revenue outstanding- excluding unapplied Medicare payments | 38.1 | 34.6 | n.a. | n.a. | ||||||||||||||||||||||||
Days of revenue outstanding- including unapplied Medicare payments | 36.3 | 21.9 | n.a. | n.a. | ||||||||||||||||||||||||
The "Footnotes to Financial Statements" are integral parts of this financial information. | ||||||||||||||||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||||||||||
FOOTNOTES TO FINANCIAL STATEMENTS | |||||||||||||||||||||||||
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013 | |||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||
(a) |
Included in the results of operations 2014 are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands): |
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Three Months Ended September 30, 2014 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Expenses related to OIG investigation | $ | (450 | ) | $ | - | $ | - | $ | (450 | ) | |||||||||||||||
Net recoveries related to litigation settlements |
- | 234 | - | 234 | |||||||||||||||||||||
Long-term incentive compensation | - | - | (1,002 | ) | (1,002 | ) | |||||||||||||||||||
Stock option expense | - | - | (977 | ) | (977 | ) | |||||||||||||||||||
Expenses of securities litigation | - | - | (138 | ) | (138 | ) | |||||||||||||||||||
Pretax impact on earnings | (450 | ) | 234 | (2,117 | ) | (2,333 | ) | ||||||||||||||||||
Income tax benefit/(cost) on the above | 171 | (91 | ) | 780 | 860 | ||||||||||||||||||||
After-tax impact on earnings | $ | (279 | ) | $ | 143 | $ | (1,337 | ) | $ | (1,473 | ) | ||||||||||||||
Nine Months Ended September 30, 2014 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Expenses related to OIG investigation | $ | (1,608 | ) | $ | - | $ | - | $ | (1,608 | ) | |||||||||||||||
Net recoveries/(expenses) related to litigation settlements |
(113 | ) | 9 | - | (104 | ) | |||||||||||||||||||
Acquisition expenses | (1 | ) | - | - | (1 | ) | |||||||||||||||||||
Stock option expense | - | - | (3,430 | ) | (3,430 | ) | |||||||||||||||||||
Long-term incentive compensation | - | - | (1,988 | ) | (1,988 | ) | |||||||||||||||||||
Expenses of securities litigation | - | - | (327 | ) | (327 | ) | |||||||||||||||||||
Interest expense: | |||||||||||||||||||||||||
Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes |
- | - | (3,389 | ) | (3,389 | ) | |||||||||||||||||||
Pretax impact on earnings | (1,722 | ) | 9 | (9,134 | ) | (10,847 | ) | ||||||||||||||||||
Income tax benefit/(cost) on the above | 654 | (3 | ) | 3,367 | 4,018 | ||||||||||||||||||||
After-tax impact on earnings | $ | (1,068 | ) | $ | 6 | $ | (5,767 | ) | $ | (6,829 | ) | ||||||||||||||
(b) |
Included in the results of operations 2013 are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands): |
||||||||||||||||||||||||
Three Months Ended September 30, 2013 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Net cost recovery/(expenses) related to OIG investigation | $ | 591 | $ | - | $ | - | $ | 591 | |||||||||||||||||
Acquisition expenses | (18 | ) | (3 | ) | - | (21 | ) | ||||||||||||||||||
Expenses related to litigation settlements | - | (443 | ) | - | (443 | ) | |||||||||||||||||||
Stock option expense | - | - | (1,629 | ) | (1,629 | ) | |||||||||||||||||||
Long-term incentive compensation | - | - | (55 | ) | (55 | ) | |||||||||||||||||||
Expenses of securities litigation | - | - | (1 | ) | (1 | ) | |||||||||||||||||||
Other operating expenses | (10,500 | ) | (961 | ) | - | (11,461 | ) | ||||||||||||||||||
Interest expense: | |||||||||||||||||||||||||
Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes |
- | - | (2,174 | ) | (2,174 | ) | |||||||||||||||||||
Pretax impact on earnings | (9,927 | ) | (1,407 | ) | (3,859 | ) | (15,193 | ) | |||||||||||||||||
Income tax benefit on the above | 3,773 | 553 | 1,419 | 5,745 | |||||||||||||||||||||
Uncertain tax position adjustments | - | - | 1,782 | 1,782 | |||||||||||||||||||||
After-tax impact on earnings | $ | (6,154 | ) | $ | (854 | ) | $ | (658 | ) | $ | (7,666 | ) | |||||||||||||
Nine Months Ended September 30, 2013 | |||||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||||||||||
Selling, general and administrative expenses: | |||||||||||||||||||||||||
Net cost recovery/(expenses) related to OIG investigation | $ | (1,444 | ) | $ | - | $ | - | $ | (1,444 | ) | |||||||||||||||
Acquisition expenses | (38 | ) | (4 | ) | - | (42 | ) | ||||||||||||||||||
Expenses related to litigation settlements | - | (1,151 | ) | - | (1,151 | ) | |||||||||||||||||||
Cost of severance arrangements | - | (302 | ) | - | (302 | ) | |||||||||||||||||||
Stock option expense | - | - | (4,732 | ) | (4,732 | ) | |||||||||||||||||||
Long-term incentive compensation | - | - | (1,161 | ) | (1,161 | ) | |||||||||||||||||||
Expenses of securities litigation | - | - | (4 | ) | (4 | ) | |||||||||||||||||||
Other operating expenses | (10,500 | ) | (15,721 | ) | - | (26,221 | ) | ||||||||||||||||||
Interest expense: | |||||||||||||||||||||||||
Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes |
- | - | (6,397 | ) | (6,397 | ) | |||||||||||||||||||
Loss on extinguishment of debt | - | - | (465 | ) | (465 | ) | |||||||||||||||||||
Pretax impact on earnings | (11,982 | ) | (17,178 | ) | (12,759 | ) | (41,919 | ) | |||||||||||||||||
Income tax benefit on the above | 4,554 | 6,742 | 4,689 | 15,985 | |||||||||||||||||||||
Uncertain tax position adjustments | - | - | 1,782 | 1,782 | |||||||||||||||||||||
After-tax impact on earnings | $ | (7,428 | ) | $ | (10,436 | ) | $ | (6,288 | ) | $ | (24,152 | ) | |||||||||||||
(c) | Under Generally Accepted Accounting Principles ("GAAP"), the Roto-Rooter segment expenses all advertising, including the cost of telephone directories, immediately upon the initial release of the advertising. Telephone directories are generally in circulation 12 months. If a directory is in circulation for a time period greater or less than 12 months, the publisher adjusts the directory billing for the change in billing period. The timing of when a telephone directory is published can and does fluctuate significantly on a quarterly basis. This "direct expensing" results in significant fluctuations in quarterly advertising expense. In the third quarters of 2014 and 2013, GAAP advertising expense for Roto-Rooter totaled $5,606,000 and $5,776,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the third quarters of 2014 and 2013 would total $6,089,000 and $6,145,000, respectively. | |
Similarly, for the first nine months of 2014 and 2013, GAAP advertising expense for Roto-Rooter totaled $18,208,000 and $17,574,00, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the first nine months of 2014 and 2013 would total $19,831,000 and $18,917,000, respectively. | ||
(d) | VITAS has nine large (greater than 450 ADC), 16 medium (greater than 200 but less than 450 ADC) and 24 small (less than 200 ADC) hospice programs. For the current Medicare cap year there are two programs with a cap liability and three programs with a Medicare cap cushion of less than 10%. | |
(e) | Adjusted diluted average shares outstanding excludes the estimated dilutive impact of the convertible notes prior to conversion of these notes on May 15, 2014 (impact of 135,000 shares for the nine months ended September 30, 2014) as this impact was entirely offset upon the exercise of the note hedges on May 15, 2014. | |
(f) | Amounts exclude indirect patient care and administrative costs, as well as Medicare Cap billing limitation. |
Source:
Chemed Corporation
David P. Williams, 513-762-6901